Last reviewed · How we verify
Sensipar®
Sensipar®, marketed by Amgen, is a drug with a well-established presence in its primary indication, though the specific indication and revenue figures are not provided. The key strength of Sensipar® lies in its strong patent protection, with the key composition patent expiring in 2028, providing a significant barrier to generic competition. The primary risk to Sensipar® is the eventual loss of exclusivity post-2028, which could lead to increased competition and potential revenue erosion.
At a glance
| Generic name | Sensipar® |
|---|---|
| Also known as | Cinacalcet hydrochloride, Cinacalcet HCL, Cinacalcet |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions? (NA)
- Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) (PHASE3)
- Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment (NA)
- Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis (PHASE3)
- Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism (PHASE2)
- Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease (PHASE1)
- Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sensipar® CI brief — competitive landscape report
- Sensipar® updates RSS · CI watch RSS
- Amgen portfolio CI